PMS2 mutations are associated with LS, a condition that increases the risk for developing CRC, uterine, ovarian, hepatobiliary, urinary tract, brain, skin, and other gastrointestinal malignancies (49, 92–95). Here, PMS2 is linked to colorectal carcinoma.